A freeze-dried formulation of bacteriophage encapsulated in biodegradable microspheres

U. Puapermpoonsin, J. Spencer, Christopher F. van der Walle

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

With the emergence of widespread antibiotic resistance, there has been renewed interest in the use of bacteriophages. While their potency, safety and specificity have underpinned their clinical potential, to date, little work has been focussed on their formulation with respect to controlled release and/or passive targeting. Here, we show that bacteriophages selective for Staphylococcus aureus or Pseudomonas aeruginosa can be encapsulated into biodegradable polyester microspheres via a modified w/o/w double emulsion-solvent extraction protocol with only a partial loss of lytic activity. Loss of lytic activity could be attributed to the exposure of the bacteriophages to the water-dichloromethane interface, with the lyophilization process itself having little effect. The microspheres were engineered to have an appropriate size and density to facilitate inhalation via a dry-powder inhaler and fluorescently labeled bacteriophages were distributed entirely within the internal porous matrix. The release profile showed a burst release phase (55-63% release within 30 min), followed by a sustained release till around 6 h, as appropriate for pulmonary delivery. Despite the poor shelf-life of the formulation, the work is proof-of-concept for the formulation and controlled delivery of bacteriophages, as suitable for the treatment of bacterial lung infections.
LanguageEnglish
Pages26-33
Number of pages7
JournalEuropean Journal of Pharmaceutics and Biopharmaceutics
Volume72
Issue number1
DOIs
Publication statusPublished - May 2009

Fingerprint

Microspheres
Bacteriophages
Dry Powder Inhalers
Lung
Polyesters
Freeze Drying
Methylene Chloride
Microbial Drug Resistance
Emulsions
Bacterial Infections
Pseudomonas aeruginosa
Inhalation
Staphylococcus aureus
Safety
Water
Therapeutics

Keywords

  • bacteriophage
  • pseudomonas
  • staphylococcus
  • inhalation
  • poly(lactic-co-glycolic acid)
  • biopharmaceutics

Cite this

Puapermpoonsin, U. ; Spencer, J. ; van der Walle, Christopher F. / A freeze-dried formulation of bacteriophage encapsulated in biodegradable microspheres. In: European Journal of Pharmaceutics and Biopharmaceutics. 2009 ; Vol. 72, No. 1. pp. 26-33.
@article{84a5eca039334f54aa6ff10a479aa405,
title = "A freeze-dried formulation of bacteriophage encapsulated in biodegradable microspheres",
abstract = "With the emergence of widespread antibiotic resistance, there has been renewed interest in the use of bacteriophages. While their potency, safety and specificity have underpinned their clinical potential, to date, little work has been focussed on their formulation with respect to controlled release and/or passive targeting. Here, we show that bacteriophages selective for Staphylococcus aureus or Pseudomonas aeruginosa can be encapsulated into biodegradable polyester microspheres via a modified w/o/w double emulsion-solvent extraction protocol with only a partial loss of lytic activity. Loss of lytic activity could be attributed to the exposure of the bacteriophages to the water-dichloromethane interface, with the lyophilization process itself having little effect. The microspheres were engineered to have an appropriate size and density to facilitate inhalation via a dry-powder inhaler and fluorescently labeled bacteriophages were distributed entirely within the internal porous matrix. The release profile showed a burst release phase (55-63{\%} release within 30 min), followed by a sustained release till around 6 h, as appropriate for pulmonary delivery. Despite the poor shelf-life of the formulation, the work is proof-of-concept for the formulation and controlled delivery of bacteriophages, as suitable for the treatment of bacterial lung infections.",
keywords = "bacteriophage, pseudomonas, staphylococcus, inhalation, poly(lactic-co-glycolic acid), biopharmaceutics",
author = "U. Puapermpoonsin and J. Spencer and {van der Walle}, {Christopher F.}",
year = "2009",
month = "5",
doi = "10.1016/j.ejpb.2008.12.001",
language = "English",
volume = "72",
pages = "26--33",
journal = "European Journal of Pharmaceutics and Biopharmaceutics",
issn = "0939-6411",
number = "1",

}

A freeze-dried formulation of bacteriophage encapsulated in biodegradable microspheres. / Puapermpoonsin, U.; Spencer, J.; van der Walle, Christopher F.

In: European Journal of Pharmaceutics and Biopharmaceutics, Vol. 72, No. 1, 05.2009, p. 26-33.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A freeze-dried formulation of bacteriophage encapsulated in biodegradable microspheres

AU - Puapermpoonsin, U.

AU - Spencer, J.

AU - van der Walle, Christopher F.

PY - 2009/5

Y1 - 2009/5

N2 - With the emergence of widespread antibiotic resistance, there has been renewed interest in the use of bacteriophages. While their potency, safety and specificity have underpinned their clinical potential, to date, little work has been focussed on their formulation with respect to controlled release and/or passive targeting. Here, we show that bacteriophages selective for Staphylococcus aureus or Pseudomonas aeruginosa can be encapsulated into biodegradable polyester microspheres via a modified w/o/w double emulsion-solvent extraction protocol with only a partial loss of lytic activity. Loss of lytic activity could be attributed to the exposure of the bacteriophages to the water-dichloromethane interface, with the lyophilization process itself having little effect. The microspheres were engineered to have an appropriate size and density to facilitate inhalation via a dry-powder inhaler and fluorescently labeled bacteriophages were distributed entirely within the internal porous matrix. The release profile showed a burst release phase (55-63% release within 30 min), followed by a sustained release till around 6 h, as appropriate for pulmonary delivery. Despite the poor shelf-life of the formulation, the work is proof-of-concept for the formulation and controlled delivery of bacteriophages, as suitable for the treatment of bacterial lung infections.

AB - With the emergence of widespread antibiotic resistance, there has been renewed interest in the use of bacteriophages. While their potency, safety and specificity have underpinned their clinical potential, to date, little work has been focussed on their formulation with respect to controlled release and/or passive targeting. Here, we show that bacteriophages selective for Staphylococcus aureus or Pseudomonas aeruginosa can be encapsulated into biodegradable polyester microspheres via a modified w/o/w double emulsion-solvent extraction protocol with only a partial loss of lytic activity. Loss of lytic activity could be attributed to the exposure of the bacteriophages to the water-dichloromethane interface, with the lyophilization process itself having little effect. The microspheres were engineered to have an appropriate size and density to facilitate inhalation via a dry-powder inhaler and fluorescently labeled bacteriophages were distributed entirely within the internal porous matrix. The release profile showed a burst release phase (55-63% release within 30 min), followed by a sustained release till around 6 h, as appropriate for pulmonary delivery. Despite the poor shelf-life of the formulation, the work is proof-of-concept for the formulation and controlled delivery of bacteriophages, as suitable for the treatment of bacterial lung infections.

KW - bacteriophage

KW - pseudomonas

KW - staphylococcus

KW - inhalation

KW - poly(lactic-co-glycolic acid)

KW - biopharmaceutics

U2 - 10.1016/j.ejpb.2008.12.001

DO - 10.1016/j.ejpb.2008.12.001

M3 - Article

VL - 72

SP - 26

EP - 33

JO - European Journal of Pharmaceutics and Biopharmaceutics

T2 - European Journal of Pharmaceutics and Biopharmaceutics

JF - European Journal of Pharmaceutics and Biopharmaceutics

SN - 0939-6411

IS - 1

ER -